4.5 Article

Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination

Journal

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume 21, Issue 7, Pages 687-696

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/ijnp/pyy027

Keywords

modafinil; astroglial connexin; FDG PET imaging; neuroglia; narcolepsy

Funding

  1. Theranexus Company
  2. Agence Nationale de la Recherche [14-CE16-0022]

Ask authors/readers for more resources

Background: Modafinil, a nonamphetaminic wake-promoting compound, is prescribed as first line therapy in narcolepsy, an invalidating disorder characterized by excessive daytime sleepiness and cataplexy. Although its mode of action remains incompletely known, recent studies indicated that modafinil modulates astroglial connexin-based gap junctional communication as administration of a low dose of flecainide, an astroglial connexin inhibitor, enhanced the wake-promoting and procognitive activity of modafinil in rodents and healthy volunteers. The aim of this study is to investigate changes in glucose cerebral metabolism in rodents, induced by the combination of modafinil + flecainide low dose (called THN102). Methods: The impact of THN102 on brain glucose metabolism was noninvasively investigated using F-18-2-fluoro-2-deoxy-Dglucose Positron Emission Tomography imaging in Sprague-Dawley male rats. Animals were injected with vehicle, flecainide, modafinil, or THN102 and further injected with F-18-2-fluoro-2-deoxy-D-glucose followed by 60-minute Positron Emission Tomography acquisition. F-18-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography images were coregistered to a rat brain template and normalized from the total brain Positron Emission Tomography signal. Voxel-to-voxel analysis was performed using SPM8 software. Comparison of brain glucose metabolism between groups was then performed. Results: THN102 significantly increased regional brain glucose metabolism as it resulted in large clusters of F-18-2-fluoro2- deoxy-D-glucose uptake localized in the cortex, striatum, and amygdala compared with control or drugs administered alone. These regions, highly involved in the regulation of sleep-wake cycle, emotions, and cognitive functions were hence quantitatively modulated by THN102. Conclusion: Data presented here provide the first evidence of a regional brain activation induced by THN102, currently being tested in a phase II clinical trial in narcoleptic patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Environmental Sciences

Usefulness of lead isotopes analysis in a pediatric case of chronic lead poisoning

L. Dufayet, J. Poupon, D. Vodovar, J. Langrand

Summary: Identifying the source of lead is crucial in managing childhood lead poisoning. By comparing lead isotopic ratios between potential sources and the patient's blood sample, the source of poisoning can be determined. This case report describes a 13-year-old girl who had lead poisoning from eating paint chips in her apartment.

ARCHIVES OF ENVIRONMENTAL & OCCUPATIONAL HEALTH (2023)

Article Otorhinolaryngology

Button Battery Ingestion in Children (PilBoulox®): A Prospective Study Describing the Clinical Course and Identifying Factors Related to Esophageal Impaction or Severe Cases

Magali Labadie, Jules-Antoine Vaucel, Arnaud Courtois, Patrick Nisse, Marion Legeay, Chantal Medernach, Anne-Marie Patat, Katharina Von Fabeck, Jean-Christophe Gallart, Christine Tournoud, Emmanuel Puskarczyk

Summary: This study aimed to identify factors related to esophageal obstruction caused by swallowed button batteries in children. A prospective multicentric observational cohort study called PilBouTox was conducted from June 1, 2016, to May 31, 2018, at French Poison Control Centers. The study included children aged 0-12 years who had swallowed button batteries. The causes of ingestion, clinical manifestations, medical management, and outcomes were recorded. The study found that anorexia, drooling, dyspnea, fever, hemodynamic instability, pallor, and pain were closely related to esophageal impaction with a relative risk greater than 30. Additionally, button batteries larger than 15 mm were associated with esophageal impaction with a relative risk of 19. The absence of initial symptoms was found to be a protective factor against esophageal impaction with a relative risk of 0.013. The study also identified dyspnea, cough, dysphagia, drooling, fever, hemodynamic instability, pain, pallor, and vomiting as symptoms closely related to major effects and death. The rapid recognition of these symptoms can help ensure prompt medical attention. The study recommended performing an X-ray as soon as possible to determine the position of the swallowed button battery.

DYSPHAGIA (2023)

Letter Neurosciences

A marked enhancement of a BLOC-1 gene, pallidin, associated with somnolent mouse models deficient in histamine transmission

Laurent Seugnet, Christelle Anaclet, Magali Perier, Jean-Francois Ghersi-Egea, Jian-Sheng Lin

CNS NEUROSCIENCE & THERAPEUTICS (2023)

Article Clinical Neurology

Sleep symptoms are essential features of long-COVID - Comparing healthy controls with COVID-19 cases of different severity in the international COVID sleep study (ICOSS-II)

Ilona Merikanto, Yves Dauvilliers, Frances Chung, Yun Kwok Wing, Luigi De Gennaro, Brigitte Holzinger, Bjorn Bjorvatn, Charles M. Morin, Thomas Penzel, Christian Benedict, Adrijana Koscec Bjelajac, Ngan Yin Chan, Colin A. Espie, Harald Hrubos-Strom, Yuichi Inoue, Maria Korman, Anne-Marie Landtblom, Damien Leger, Kentaro Matsui, Sergio Mota-Rolim, Michael R. Nadorff, Giuseppe Plazzi, Catia Reis, Juliana Yordanova, Markku Partinen

Summary: An international survey study reveals that post-acute sequelae of COVID-19 symptoms are more prevalent among severe cases and long-lasting sleep problems are at the core of these symptoms. Understanding the importance of sleep-related symptoms has clinical relevance in diagnosing and treating long-COVID.

JOURNAL OF SLEEP RESEARCH (2023)

Article Clinical Neurology

Home nocturnal infrared video to record non-rapid eye movement sleep parasomnias

Regis Lopez, Lucie Barateau, Sofiene Chenini, Anna Laura Rassu, Yves Dauvilliers

Summary: This study evaluated the feasibility, acceptability, and usefulness of home nocturnal infrared video recording in assessing the frequency and complexity of non-rapid eye movement sleep parasomnias in adults, as well as monitoring treatment response.

JOURNAL OF SLEEP RESEARCH (2023)

Article Clinical Neurology

Rapid eye movement sleep duration during the multiple sleep latency test to diagnose hypocretin-deficient narcolepsy

Regis Lopez, Lucie Barateau, Anna Laura Rassu, Elisa Evangelista, Sofiene Chenini, Sabine Scholz, Isabelle Jaussent, Yves Dauvilliers

Summary: The study aims to evaluate alternative measures of the multiple sleep latency test (MSLT) for identifying hypocretin-deficiency in patients with hypersomnolence, including narcolepsy patients. The results show that compared to the current neurophysiological standard criteria, alternative MSLT measures are more effective in identifying hypocretin-deficient patients with hypersomnolence and narcolepsy. Daytime REM sleep duration is highlighted as a relevant neurophysiological biomarker of hypocretin-deficiency, which can be used in clinical and research settings.

SLEEP (2023)

Article Clinical Neurology

Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder

Dieter Kunz, Yves Dauvilliers, Heike Benes, Diego Garcia-Borreguero, Giuseppe Plazzi, Dalma Seboek Kinter, Preciosa Coloma, Magdalene Rausch, Mouna Sassi-Sayadi, Stephen Thein

Summary: In this 40-week extension study, Daridorexant was found to be safe and well-tolerated for long-term treatment of insomnia disorder. It improved sleep and daytime functioning, with the most pronounced effects observed with the 50 mg dose.

CNS DRUGS (2023)

Article Medicine, General & Internal

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

Alisa M. Higgins, Lindsay R. Berry, Elizabeth Lorenzi, Srinivas Murthy, Zoe McQuilten, Paul R. Mouncey, Farah Al-Beidh, Djillali Annane, Yaseen M. Arabi, Abi Beane, Wilma Van Bentum-Puijk, Zahra Bhimani, Marc J. M. Bonten, Charlotte A. Bradbury, Frank M. Brunkhorst, Aiden Burrell, Adrian Buzgau, Meredith Buxton, Walton N. Charles, Matthew Cove, Michelle A. Detry, Lise J. Estcourt, Elizabeth O. Fagbodun, Mark Fitzgerald, Timothy D. Girard, Ewan C. Goligher, Herman Goossens, Rashan Haniffa, Thomas Hills, Christopher M. Horvat, David T. Huang, Nao Ichihara, Francois Lamontagne, John C. Marshall, Daniel F. McAuley, Anna McGlothlin, Shay P. McGuinness, Bryan J. McVerry, Matthew D. Neal, Alistair D. Nichol, Rachael L. Parke, Jane C. Parker, Karen Parry-Billings, Sam E. C. Peters, Luis F. Reyes, Kathryn M. Rowan, Hiroki Saito, Marlene S. Santos, Christina T. Saunders, Ary Serpa-Neto, Christopher W. Seymour, Manu Shankar-Hari, Lucy M. Stronach, Alexis F. Turgeon, Anne M. Turner, Frank L. van de Veerdonk, Ryan Zarychanski, Cameron Green, Roger J. Lewis, Derek C. Angus, Colin J. McArthur, Scott Berry, Lennie P. G. Derde, Anthony C. Gordon, Steve A. Webb, Patrick R. Lawler

Summary: The longer-term effects of therapies for critically ill COVID-19 patients are unknown. In this study, 4869 patients were randomized to receive different interventions, and it was found that treatment with IL-6 receptor antagonists and antiplatelet agents significantly improved survival rates after 180 days. These findings suggest that most therapies have consistent effects over a 6-month period.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Article Clinical Neurology

Brain-derived neurotrophic factor (BDNF) variants and promoter I methylation are associated with prolonged nocturnal awakenings in older adults

Marie-Laure Ancelin, Isabelle Jaussent, Karen Ritchie, Alain Besset, Joanne Ryan, Yves Dauvilliers

Summary: This study examines the association between BDNF variants and promoter I methylation with sleep disturbances in older adults. The results show that wake time after sleep onset (WASO) is associated with four SNPs in participants not taking psychotropic drugs, while the associations are either not significant or in the reverse direction in participants taking drugs. Higher BDNF methylation levels are found in participants with long WASO, and this varies depending on psychotropic drug use.

JOURNAL OF SLEEP RESEARCH (2023)

Article Clinical Neurology

Cognitive strategies to improve symptoms of restless legs syndrome

Sofiene Chenini, Lucie Barateau, Lily Guiraud, Marie-Lou Rollin, Regis Lopez, Isabelle Jaussent, Severine Beziat, Yves Dauvilliers

Summary: One-third of patients with restless legs syndrome reported a decrease in symptoms during cognitive activities, and this improvement was confirmed during a sustained cognitive task.

JOURNAL OF SLEEP RESEARCH (2023)

Letter Critical Care Medicine

Assessing effectiveness of whole bowel irrigation in poisoning: A laudable effort but still insufficient evidence

Dominique Vodovar, Laurene Dufayet, Bruno Megarbane

AUSTRALIAN CRITICAL CARE (2023)

Article Clinical Neurology

Metabolic disturbances in children with narcolepsy: a retrospective study

Min Zhang, Marine Thieux, Laura Arvis, Jian-Sheng Lin, Aurore Guyon, Sabine Plancoulaine, Carine Villanueva, Patricia Franco

Summary: The prevalence of metabolic syndrome (MS) in children with narcolepsy was investigated, and their clinical and sleep characteristics were evaluated according to different components of MS. It was found that 17.2% of children with narcolepsy had MS, with insulin resistance being the core metabolic disturbance. Children with at least two components of MS had more severe daytime sleepiness and a higher prevalence of night-eating behaviors. Early evaluation and management may be beneficial for these children to prevent future complications.

SLEEP (2023)

Article Clinical Neurology

Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial

Yves Dauvilliers, Thomas Roth, Richard Bogan, Michael J. Thorpy, Anne Marie Morse, Asim Roy, Jordan Dubow, Jennifer Gudeman

Summary: This study evaluated the efficacy of extended-release once-nightly sodium oxybate (ON-SXB; FT218) compared to placebo for daytime sleepiness and disrupted nighttime sleep in narcolepsy type 1 (NT1) and 2 (NT2). The results showed significant improvements in sleep latency, sleep quality, nocturnal arousals, and daytime sleepiness for both NT1 and NT2 subgroups treated with ON-SXB compared to placebo.

SLEEP (2023)

Article Clinical Neurology

Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem

Tobias Di Marco, Thomas E. Scammell, Michael Meinel, Dalma Seboek Kinter, Alexandre N. Datta, Gary Zammit, Yves Dauvilliers

Summary: The study aimed to explore the effect of daridorexant, a dual orexin receptor antagonist, on nighttime wake bouts and their correlation with daytime functioning. Results showed that daridorexant reduced the number and duration of long wake bouts during the night compared with placebo, corresponding with improved daytime functioning.

CNS DRUGS (2023)

Review Immunology

The immunopathogenesis of narcolepsy type 1

Roland S. Liblau, Daniela Latorre, Birgitte R. Kornum, Yves Dauvilliers, Emmanuel J. Mignot

Summary: Narcolepsy type 1 (NT1) is a chronic sleep disorder caused by the loss of certain hypothalamic neurons. It is suspected to have an immune-mediated basis, supported by genetic evidence and increased incidence after vaccination. The search for antigens recognized by pathogenic T cell response in NT1 is ongoing, and animal models provide insights into the roles of autoreactive T cells.

NATURE REVIEWS IMMUNOLOGY (2023)

No Data Available